Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...
Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a treatment could be difficult. By Gina Kolata Is there a way to use the body’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results